PMID- 32595100
OWN - NLM
STAT- MEDLINE
DCOM- 20221122
LR  - 20230321
IS  - 1573-2509 (Electronic)
IS  - 0920-9964 (Print)
IS  - 0920-9964 (Linking)
VI  - 249
DP  - 2022 Nov
TI  - White matter alterations and the conversion to psychosis: A combined diffusion 
      tensor imaging and glutamate (1)H MRS study.
PG  - 85-92
LID - S0920-9964(20)30358-3 [pii]
LID - 10.1016/j.schres.2020.06.006 [doi]
AB  - INTRODUCTION: Widespread white matter abnormalities and alterations in glutamate 
      levels have been reported in patients with schizophrenia. We hypothesized that 
      alterations in white matter integrity and glutamate levels in individuals at 
      clinical high risk (CHR) for psychosis are associated with the subsequent 
      development of psychosis. METHODS: Participants included 33 antipsychotic naive 
      CHR (Female 7/Male 26, Age 19.55 (4.14) years) and 38 healthy controls (Female 
      10/Male 28, Age 20.92 (3.37) years). Whole brain diffusion tensor imaging for 
      fractional anisotropy (FA) and right frontal white matter proton magnetic 
      resonance spectroscopy for glutamate levels were acquired. CHR participants were 
      clinically followed for 2 years to determine conversion to psychosis. RESULTS: 
      CHR participants that transitioned to psychosis (N = 7, 21%) were characterized 
      by significantly lower FA values in the posterior thalamic radiation compared to 
      those who did not transition and healthy controls. In the CHR group that 
      transitioned to psychosis only, positive exploratory correlations between 
      glutamate levels and FA values of the posterior thalamic radiation and the 
      retrolenticular part of the internal capsule and a negative correlation between 
      glutamate levels and the cingulum FA values were found. CONCLUSION: The results 
      of the present study highlight that alterations in white matter structure and 
      glutamate are related with the conversion to psychosis.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Leon-Ortiz, Pablo
AU  - Leon-Ortiz P
AD  - Laboratory of Experimental Psychiatry, Instituto Nacional de Neurologia y 
      Neurocirugia, Mexico City, Mexico; Department of Education, Instituto Nacional de 
      Neurologia y Neurocirugia, Mexico City, Mexico.
FAU - Reyes-Madrigal, Francisco
AU  - Reyes-Madrigal F
AD  - Laboratory of Experimental Psychiatry, Instituto Nacional de Neurologia y 
      Neurocirugia, Mexico City, Mexico.
FAU - Kochunov, Peter
AU  - Kochunov P
AD  - Maryland Psychiatric Research Center, Department of Psychiatry, University of 
      Maryland School of Medicine, Baltimore, United States of America.
FAU - Gomez-Cruz, Gladys
AU  - Gomez-Cruz G
AD  - Laboratory of Experimental Psychiatry, Instituto Nacional de Neurologia y 
      Neurocirugia, Mexico City, Mexico.
FAU - Moncada-Habib, Tomas
AU  - Moncada-Habib T
AD  - Laboratory of Experimental Psychiatry, Instituto Nacional de Neurologia y 
      Neurocirugia, Mexico City, Mexico.
FAU - Malacara, Melanie
AU  - Malacara M
AD  - Laboratory of Experimental Psychiatry, Instituto Nacional de Neurologia y 
      Neurocirugia, Mexico City, Mexico.
FAU - Mora-Duran, Ricardo
AU  - Mora-Duran R
AD  - Emergency Department, Hospital Fray Bernardino Alvarez, Mexico City, Mexico.
FAU - Rowland, Laura M
AU  - Rowland LM
AD  - Maryland Psychiatric Research Center, Department of Psychiatry, University of 
      Maryland School of Medicine, Baltimore, United States of America.
FAU - de la Fuente-Sandoval, Camilo
AU  - de la Fuente-Sandoval C
AD  - Laboratory of Experimental Psychiatry, Instituto Nacional de Neurologia y 
      Neurocirugia, Mexico City, Mexico; Neuropsychiatry Department, Instituto Nacional 
      de Neurologia y Neurocirugia, Mexico City, Mexico. Electronic address: 
      fcamilo@unam.mx.
LA  - eng
GR  - R01 EB015611/EB/NIBIB NIH HHS/United States
GR  - RF1 NS114628/NS/NINDS NIH HHS/United States
GR  - RF1 MH123163/MH/NIMH NIH HHS/United States
GR  - R01 AA012207/AA/NIAAA NIH HHS/United States
GR  - S10 OD023696/OD/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200625
PL  - Netherlands
TA  - Schizophr Res
JT  - Schizophrenia research
JID - 8804207
RN  - 3KX376GY7L (Glutamic Acid)
SB  - IM
MH  - Humans
MH  - Male
MH  - Female
MH  - Young Adult
MH  - Adult
MH  - Diffusion Tensor Imaging/methods
MH  - *White Matter/diagnostic imaging/pathology
MH  - Glutamic Acid
MH  - *Psychotic Disorders/diagnostic imaging/pathology
MH  - *Schizophrenia/diagnostic imaging/pathology
MH  - Anisotropy
MH  - Brain/pathology
MH  - Diffusion Magnetic Resonance Imaging
PMC - PMC10025976
MID - NIHMS1874077
OTO - NOTNLM
OT  - Clinical high risk
OT  - Conversion to psychosis
OT  - Diffusion tensor imaging
OT  - Glutamate
OT  - Magnetic resonance spectroscopy
COIS- Declaration of competing interest Pablo Leon-Ortiz has served as a speaker for 
      Shire Pharmaceuticals, Francisco Reyes-Madrigal has served as a speaker for 
      Janssen (Johnson & Johnson) and AstraZeneca, R. Mora-Duran has served as a 
      speaker for Schwabe Pharmaceuticals, Laura M. Rowland has served as a consultant 
      for Otsuka America Pharmaceutical Inc., and Camilo de la Fuente-Sandoval has 
      served as a consultant for Janssen (Johnson & Johnson). The rest of the authors 
      report no biomedical financial interests or potential conflicts of interest.
EDAT- 2020/07/01 06:00
MHDA- 2022/11/23 06:00
PMCR- 2023/03/20
CRDT- 2020/06/30 06:00
PHST- 2020/01/27 00:00 [received]
PHST- 2020/06/08 00:00 [revised]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2022/11/23 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
PHST- 2023/03/20 00:00 [pmc-release]
AID - S0920-9964(20)30358-3 [pii]
AID - 10.1016/j.schres.2020.06.006 [doi]
PST - ppublish
SO  - Schizophr Res. 2022 Nov;249:85-92. doi: 10.1016/j.schres.2020.06.006. Epub 2020 
      Jun 25.